Drug intelligence / Profile preview

AVT32

Development stage: Phase 1
Lead developer: Alvotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AVT32 is a biosimilar candidate to Keytruda (pembrolizumab), a monoclonal antibody. It is being co-developed, manufactured, and commercialized through a collaboration between Alvotech and Dr. Reddy's Laboratories. This partnership aims to expedite the development process and broaden the global availability of the biosimilar, with both parties holding commercialization rights globally, subject to certain exceptions. As a biosimilar of pembrolizumab, AVT32 is expected to act as a checkpoint inhibitor by targeting Programmed cell death protein 1 (PD-1), thereby enhancing the body's anti-tumor immune response.

Other names: pembrolizumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on AVT32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVT32.

Explore the full profile